NCT01915589 - Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 16, 2013

Primary Completion Date

October 8, 2014

Study Completion Date

October 8, 2014

Conditions

Carcinoma, Hepatocellular

Interventions

DRUG

Refametinib (BAY86-9766)

All patients who meet the entry criteria will receive refametinib 50 mg (2x20 mg + 1x10 mg capsules or 50 mg tablet) bid.

Trial Locations (58)

704

Tainan City

1023

Auckland

1062

Budapest

1070

Bruxelles - Brussel

1200

Bruxelles - Brussel

1211

Geneva

3000

Leuven

3010

Bern

4032

Debrecen

6000

Charleroi

8036

Graz

8330

Kaohsiung City

9000

Ghent

10029

New York

10210

Bangkok

10330

Bangkok

10700

Bangkok

13005

Marseille

13353

Berlin

14642

Rochester

15706

Santiago de Compostela

20089

Milan

20133

Milan

30625

Hanover

33136

Miami

33612

Tampa

34059

Montpellier

36071

Pontevedra

41404

Daegu

45136

Essen

46010

Valencia

49241

Busan

54511

Vandœuvre-lès-Nancy

55131

Mainz

59037

Lille

63003

Clermont-Ferrand

69120

Heidelberg

81377

München

94010

Créteil

20007-2197

Washington D.C.

128 08

Prague

Unknown

Shatin

277-8577

Kashiwa-shi

650-0017

Kobe

570-8507

Moriguchi

541-8567

Osaka

589-8511

Osakasayama-shi

411-8777

Sunto

329-0498

Shimotsuke

104-0045

Chuo-ku

543-8555

Osaka

420-8527

Shizuoka

03080

Seoul

05505

Seoul

135-710

Seoul

08035

Barcelona

03010

Alicante

B15 2TT

Birmingham